Low disease activity state in juvenile-onset systemic lupus erythematosus

dc.authorid0000-0001-7490-7076
dc.authorid0000-0002-1386-4575
dc.authorid0000-0003-3014-5692
dc.authorid0000-0002-9186-3068
dc.authorid0000-0001-9801-925X
dc.authorid0000-0001-5602-4595
dc.authorid0000-0003-2575-6309
dc.contributor.authorOzturk, Kubra
dc.contributor.authorCaglayan, Sengul
dc.contributor.authorTanatar, Ayse
dc.contributor.authorBaglan, Esra
dc.contributor.authorOtar, Gulcin Yener
dc.contributor.authorKayaalp, Gulsah Kavrul
dc.contributor.authorKaradağ, Serife Gul
dc.date.accessioned2025-05-10T19:41:28Z
dc.date.issued2021
dc.departmentİstanbul Medeniyet Üniversitesi
dc.description.abstractObjectives To determine the rate of achieving The Lupus Low Disease Activity State (LLDAS) in children with systemic lupus erythematosus (SLE) for tracing pertinent treatment modalities. Methods A total of 122 juvenile-onset SLE (jSLE) patients from six pediatric rheumatology centers in Turkey were enrolled in the study. LLDAS-50 was defined as encountering LLDAS for at least 50% of the observation time. According to the achievement of LLDAS-50, clinical features, immunological profiles, and treatments of patients with jSLE have been revealed. Results LLDAS of any duration was achieved by 82% of the cohort. Although only 10.8% of the patients achieved remission, 68.9% reached LLDAS-50. A significant difference was found between patients who reached LLDAS-50 and those who did not, in terms of the time to reach low-dose corticosteroid treatment (p = 0.002), the presence of subacute cutaneous findings (p = 0.007), and the presence of proteinuria (p = 0.002). Both of the groups were under similar treatment approaches. However, the number of patients being treated with corticosteroids at the last visit was found to be significantly higher in patients who achieved LLDAS-50 (p<0.001). Conclusion Targeting LLDAS in jSLE, even with long-term, low-dose corticosteroid use, seems to be an achievable goal in clinical practice.
dc.identifier.doi10.1177/09612033211054399
dc.identifier.endpage2150
dc.identifier.issn0961-2033
dc.identifier.issn1477-0962
dc.identifier.issue13
dc.identifier.pmid34723709
dc.identifier.scopus2-s2.0-85118647890
dc.identifier.scopusqualityQ2
dc.identifier.startpage2144
dc.identifier.urihttps://doi.org/10.1177/09612033211054399
dc.identifier.urihttps://hdl.handle.net/20.500.14730/10343
dc.identifier.volume30
dc.identifier.wosWOS:000715281900001
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherSage Publications Ltd
dc.relation.ispartofLupus
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WOS_20250302
dc.subjectJuvenile-onset systemic lupus erythematosus
dc.subjectlow lupus disease activity state
dc.subjectLLDAS-50
dc.titleLow disease activity state in juvenile-onset systemic lupus erythematosus
dc.typeArticle

Dosyalar